Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. more
Time Frame | CRSP | Sector | S&P500 |
---|---|---|---|
1-Week Return | -2.07% | 0.71% | 1.64% |
1-Month Return | -24.04% | -4% | -2.94% |
3-Month Return | -11.64% | 0.84% | 3.53% |
6-Month Return | 37.84% | 12.62% | 22.95% |
1-Year Return | 10.81% | 7.99% | 26.43% |
3-Year Return | -60.28% | 18.97% | 26.19% |
5-Year Return | 31.42% | 71.39% | 86.42% |
10-Year Return | 282.61% | 184.83% | 224.48% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 289.59M | 543.00K | 913.08M | 436.00K | 370.00M | [{"date":"2019-12-31","value":31.72,"profit":true},{"date":"2020-12-31","value":0.06,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.05,"profit":true},{"date":"2023-12-31","value":40.52,"profit":true}] |
Cost of Revenue | 179.36M | 269.41M | 101.18M | 110.25M | 130.25M | [{"date":"2019-12-31","value":66.58,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":37.56,"profit":true},{"date":"2022-12-31","value":40.92,"profit":true},{"date":"2023-12-31","value":48.35,"profit":true}] |
Gross Profit | 289.59M | (268.86M) | 913.08M | (109.81M) | 239.75M | [{"date":"2019-12-31","value":31.72,"profit":true},{"date":"2020-12-31","value":-29.45,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-12.03,"profit":false},{"date":"2023-12-31","value":26.26,"profit":true}] |
Gross Margin | 100.00% | (49514.55%) | 100.00% | (25186.70%) | 64.80% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-49514.55,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-25186.7,"profit":false},{"date":"2023-12-31","value":64.8,"profit":true}] |
Operating Expenses | 242.85M | 354.98M | 539.55M | 563.35M | 462.29M | [{"date":"2019-12-31","value":43.11,"profit":true},{"date":"2020-12-31","value":63.01,"profit":true},{"date":"2021-12-31","value":95.78,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":82.06,"profit":true}] |
Operating Income | 46.74M | (354.44M) | 373.53M | (673.16M) | (222.54M) | [{"date":"2019-12-31","value":12.51,"profit":true},{"date":"2020-12-31","value":-94.89,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-180.22,"profit":false},{"date":"2023-12-31","value":-59.58,"profit":false}] |
Total Non-Operating Income/Expense | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | 67.31M | (348.06M) | 379.53M | (650.50M) | (150.72M) | [{"date":"2019-12-31","value":17.73,"profit":true},{"date":"2020-12-31","value":-91.71,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-171.4,"profit":false},{"date":"2023-12-31","value":-39.71,"profit":false}] |
Income Taxes | 448.00K | 809.00K | 1.87M | (325.00K) | 2.89M | [{"date":"2019-12-31","value":15.51,"profit":true},{"date":"2020-12-31","value":28.01,"profit":true},{"date":"2021-12-31","value":64.75,"profit":true},{"date":"2022-12-31","value":-11.25,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | 66.86M | (348.87M) | 377.66M | (650.17M) | (153.61M) | [{"date":"2019-12-31","value":17.7,"profit":true},{"date":"2020-12-31","value":-92.38,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-172.16,"profit":false},{"date":"2023-12-31","value":-40.67,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 66.86M | (348.87M) | 377.66M | (650.17M) | (153.61M) | [{"date":"2019-12-31","value":17.7,"profit":true},{"date":"2020-12-31","value":-92.38,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-172.16,"profit":false},{"date":"2023-12-31","value":-40.67,"profit":false}] |
EPS (Diluted) | 0.97 | (5.27) | 4.42 | (8.37) | (1.96) | [{"date":"2019-12-31","value":21.95,"profit":true},{"date":"2020-12-31","value":-119.23,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-189.37,"profit":false},{"date":"2023-12-31","value":-44.34,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CRSP | |
---|---|
Cash Ratio | 15.57 |
Current Ratio | 17.54 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CRSP | |
---|---|
ROA (LTM) | -6.22% |
ROE (LTM) | -8.17% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CRSP | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.16 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.84 |
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 1.18 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CRSP | |
---|---|
Trailing PE | NM |
Forward PE | 23.36 |
P/S (TTM) | 13.87 |
P/B | 2.74 |
Price/FCF | NM |
EV/R | 9.99 |
EV/Ebitda | NM |
PEG | NM |
CRISPR Therapeutics (NASDAQ:CRSP) stock has been slowly heading lower in recent months, and I don’t think that’s fair. Having reached highs near $9…
Biotech stocks were among the worst performers in 2023. And so far in 2024, investors are still waiting on the recovery rally. Many small-cap biotech stocks are being held back by the Fed’s more restrictive stance on interest rates. But even some of the large-cap names with commercially available drugs that are household names are also underperforming the market. But “some” isn’t the same as “all.” In a stock picker’s market, you want to find the stocks that have a chance to outperform. One way to find these stocks is to look at analyst ratings. The three stocks in this article all have multiple Strong Buy ratings from analysts in addition to bullish price targets. Two of the stocks mentioned are Dividend Kings, which give you the added benefit of compounding as you hold the stock. Analyst ratings aren’t always an exact correlation, but they are a helpful way to narrow your focus and hone your research. That’s particularly important when it comes to the notoriously volatile biotech sector.
These companies are in the early days of their growth stories.
CRISPR Therapeutics (NASDAQ:CRSP) stock has been falling over the past month. Without any milestone announcements since it gained its second U.S. r…
Last year was a tough one for biotech stocks . The Securities and Exchange Commission reported 41 bankruptcies following the Fed’s interest rate hiking cycle, making it difficult to finance debt. Yet, by the end of the year, the biotech sector started to recover. Over one year, BlackRock’s iShares Biotechnology ETF (NASDAQ: IBB ) is now up 10%, but down -1.3% year-to-date. Due to negative market sentiment, some biotech stocks are more discounted than others. But which biotech stocks have sounder fundamentals? CRISPR Therapeutics (CRSP) Source: rafapress / Shutterstock.com CRISPR (NASDAQ: CRSP ), which stands for Clustered Regularly Interspaced Short Palindromic Repeats is a gene-editing tool adapted from bacterial defense to apply as molecular scissors. By cutting DNA fragments at certain points, CRISPR tech can potentially correct faulty genes and eliminate conditions stemming from them. In January, the company announced the FDA approval of gene-edited cell therapy CASGEVY for treating patients who require regular blood transfusions to stay alive.
Crispr Therapeutics AG (CRSP) share price today is $53.91
Yes, Indians can buy shares of Crispr Therapeutics AG (CRSP) on Vested. To buy Crispr Therapeutics AG from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CRSP stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Crispr Therapeutics AG (CRSP) via the Vested app. You can start investing in Crispr Therapeutics AG (CRSP) with a minimum investment of $1.
You can invest in shares of Crispr Therapeutics AG (CRSP) via Vested in three simple steps:
The 52-week high price of Crispr Therapeutics AG (CRSP) is $91.1. The 52-week low price of Crispr Therapeutics AG (CRSP) is $37.55.
The price-to-earnings (P/E) ratio of Crispr Therapeutics AG (CRSP) is NM
The price-to-book (P/B) ratio of Crispr Therapeutics AG (CRSP) is 2.74
The dividend yield of Crispr Therapeutics AG (CRSP) is 0.00%
The market capitalization of Crispr Therapeutics AG (CRSP) is $4.58B
The stock symbol (or ticker) of Crispr Therapeutics AG is CRSP